



Catalog Number:	MO25029	Host:	Mouse
Product Type:	IgG ₁ kappa	Species Reactivity:	Human
Immunogen Sequence:	Human BRCA1 (residues 1314-1864).	Format:	0.1 ml Mouse ascites containing 0.1% sodium.

Applications: Immunofluorescence: Assay dependent (See Applications Notes-Protocol).
Western Blot 1:1,000

Dilutions listed as a recommendation. Optimal dilution should be determined by investigator.

Storage: Store frozen. Aliquot as undiluted antisera and immediately place at -20°C. Antisera may have become trapped in top of vial during shipping. Centrifugation of vial is recommended before opening. Stable for at least 6 months at -20°C. Repeated freeze/thaw cycles compromise the integrity of the antiserum.

Application Notes

This antibody does not work in Rat.

Positive Control: Pig RPE (Retinal Pigment Epithelium) whole cell extract. This antibody recognizes a band at ~68 kDa

Western Blot Procedure

1. Run cell lysates** on an SDS-PAGE gel.
2. Transfer the proteins to PVDF.
3. Block the membrane in 1% Carnation instant milk in PBS + 0.1% Tween 20 (with 0.1mM CaCl₂ and 1mM MgCl₂) for 1 hour at RT.
4. Dilute the antibody to 1:1,000 in 10 ml of fresh blocking buffer and incubate for 1 hour at RT.
5. Wash the membrane with blocking buffer, 3x 5-10 minutes.
6. Dilute the secondary antibody in fresh blocking buffer, as recommended by the secondary vendor and incubate for 1hour at RT.
7. Wash the membrane with blocking buffer, 5x 8 minutes and rinse 1x with PBS (containing 0.1mM CaCl₂ and 1mM MgCl₂).
8. Detect the protein-antibody complex with alkaline phosphatase, if using NBT/BCIP or with HRP, if using ECL.

**Cell Lysate Preparation

- A. Lysates were prepared in lysis buffer [50mM Tris·HCl, pH 8 / 120mM NaCl / 0.5% Nonidet P-40 / 10 ug/ml aprotinin / 10 ug/ml leupeptin / 1mM phenylmethylsulfonyl fluoride / 1mM sodium orthovanadate].
- B. Total protein content was determined by bicinchoninic acid assay (Pierce).

Immunofluorescence

1. Paraffin slides deparaffinize as follows:
 - a. 2x 5 min in Xylene
 - b. 2x 5 min in 100% ethanol
 - c. 2x 5 min in 95% ethanol
 - d. 1x 5 min in 70% ethanol
 - e. 1x 5 min or more in PBS
2. Cryosections:
 - a. air dry for >30 min

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. -V2/08/2012

- b. rehydrate in PBS-CM (PBS + 0.1mM CaCl₂ and 1mM MgCl₂) + 3% BSA
3. Use pap pen to draw circles around sections
4. Block in PBS-CM + BSA for 30 min at RT
5. Dilute Bestrophin [cat# NB 300-164] in PBS-CM + BSA and incubate at RT for 1 hour or overnight at 4°C.
6. Wash the slides with PBS-CM + BSA 5x 5 min
7. Dilute the secondary antibody in PBS-CM + BSA and incubate at RT for >1 hour (if staining nuclei with propidium iodide add saponin to 0.1% and RNase A at 1:500)
8. Wash 3x 8 min with PBS-CM + BSA and then 1x 5 min with PBS-CM
 - a. If staining nuclei with DAPI or propidium iodide, dilute into PBS-CM at 1:1000
 - b. Wash 3x with PBS-CM, if using propidium iodide
 - c. Proceed directly to step 9, if using DAPI
9. Mount in Flourmount.

NOTE: Immunofluorescence Considerations

1. Aldehyde fixatives (ie: PFA and formalin) will not work in immunofluorescence with this antibody.
 - A) Transfected cells on coverslips can be fixed in acetone or methanol, as can tissue.
 - B) Paraformaldehyde for paraffin sections can be used if the tissue is subject to heat and pressure mediated antigen retrieval [see specific reference 1 on datasheet]
2. To date, endogenous protein in human or pig eyes cannot be detected, even in methanol/acetone fixed sections directly.
3. Immunohistochemistry, using this antibody, has been done using the vector ABC kit, which includes a signal amplification step.

Description/Data:

BRCA1 (breast and ovarian cancer susceptibility protein 1) is a RING finger protein containing a BRCT domain. BRCA1 exists as a heterodimer with 22 possible isoforms. The full length protein has a reported molecular weight of 208 kD. BRCA1 localizes to the mitotic spindle microtubules, centriole walls, pericentriolar fibers at centrosomes. Unphosphorylated BRCA1 localizes on chromosomes from metaphase through telophase; phosphorylated BRCA1 resides in inner chromosomal structure, centrosome, cleavage furrow during prophase through telophase, and relocates to the perinuclear region when cells are subjected to IR or UV radiation in S phase. BRCA1 acts as a tumor suppressor and can function as a secreted growth inhibitory protein, participate in transcription coupled repair of oxidative DNA damage, X-chromosome inactivation, and can function as a E3 ubiquitin ligase. BRCA1 can be transcriptionally downregulated by Ets-2, Brg-1, and Hmga-1. BRCA1 can be modified by glycosylation, ubiquitination and phosphorylation by CDK4, ATM/ATR, cdk2, and hChk2. The BRCA1 protein has been reported to interact with RNA polymerase II holoenzyme and BARD1. BRCA1 contains at least two nuclear localization signals and is proposed to be a tumor suppressor protein. It is a serine phosphoprotein that undergoes hyperphosphorylation during late G1 and S phases of the cell cycle and is transiently dephosphorylated early after M phase. BRCA1 protein alters in a qualitative and quantitative manner during cell cycle progression. The amount of BRCA1 protein is highest during S phase and remains elevated toward G2 / M, before it declines in early G1 phase. Inherited loss of BRCA1 function confers an increased susceptibility for both breast and ovarian cancer.




Image: BRCA1 in MCF-7 whole cell lysate. 12 minute ECL exposure.

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012

www.neuromics.com

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
 phone 866-350-1500 • fax 612-677-3976 • e-mail: pshuster@neuromics.com